Lumida
/CPRX
⌘K
Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

CPRX
$31.49USD+0.03%+0.01 today

MARKET CAP

3.9B

P/E (TTM)

18.1x

FWD P/E

DAY RANGE

$31 – $32

52W RANGE

$19
$33

AI Summary

Stalk
StalkLow

CPRX is locked in a flat, range-bound structure with overlapping EMAs at the same level and extreme overbought readings; while the medium-term Stage 1 base supports a bullish bias, short-term execution is deferred until a clear pullback into the EMAs.

  • 19.8% YOY revenue growth to $589M in 2025 driven by Ferdaps and Agamri.
  • Cash reserves of $709.2M provide strategic R&D and buyback flexibility.
  • Generic FICOMPA entry expected to erode significant revenue.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$140.8M$214.2M$398.2M$491.7M$589.0M
YoY %+18.3%+52.1%+85.9%+23.5%+19.8%
P / Sales5.2x9.4x4.9x5.3x5.0x
EV / Sales4.2x8.3x4.7x4.5x4.1x
Gross Profit, Adj.$118.9M$179.8M$346.2M$422.9M$501.7M
YoY %+16.6%+51.2%+92.6%+22.1%+18.6%
Margin %84.5%83.9%86.9%86.0%85.2%
EV / Gross Profit5.0x9.9x5.5x5.2x4.8x
EBITDA, Adj.$52.6M$103.1M$119.7M$232.9M$295.7M
YoY %+27.0%+96.0%+16.1%+94.6%+26.9%
Margin %37.3%48.1%30.1%47.4%50.2%
EV / EBITDA11.2x17.3x15.8x9.5x8.2x
EBIT$52.4M$101.8M$86.8M$195.1M$257.8M
YoY %+26.8%+94.4%-14.8%+124.8%+32.1%
Margin %37.2%47.5%21.8%39.7%43.8%
EV / EBIT11.2x17.6x21.8x11.3x9.4x
Net Income$39.5M$83.1M$71.4M$163.9M$214.3M
YoY %-47.3%+110.4%-14.0%+129.5%+30.8%
Net Margin28.0%38.8%17.9%33.3%36.4%
EPS (GAAP)$0.37$0.75$0.63$1.31$1.68
YoY %-47.9%+102.7%-16.0%+107.9%+28.2%